Key Points
- Opus Genetics director Fighting Blindness Foundation sold 4,000,000 shares on Dec. 9 at an average of $2.15 for roughly $8.6M, cutting their holding by 42.14% to 5,492,171 shares (valued ≈ $11.8M).
- Opus Genetics is a clinical-stage ophthalmic biopharma with a market cap of $168.26M and reported negative earnings (quarterly EPS -$0.12; consensus forecast -$1.22 for the fiscal year), indicating it remains unprofitable.
- Analyst views are mixed: MarketBeat shows a consensus Moderate Buy with a $7.86 target, while individual ratings range from sell to strong-buy (e.g., Piper Sandler overweight $7, B. Riley buy $9).
Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) Director Fighting Blindness Foundation sold 4,000,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $2.15, for a total transaction of $8,600,000.00. Following the sale, the director owned 5,492,171 shares of the company's stock, valued at $11,808,167.65. The trade was a 42.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Opus Genetics Price Performance
NASDAQ IRD opened at $2.44 on Friday. Opus Genetics, Inc. has a 1 year low of $0.65 and a 1 year high of $2.59. The business's fifty day moving average is $2.03 and its two-hundred day moving average is $1.48. The stock has a market capitalization of $168.26 million, a P/E ratio of -1.30 and a beta of 0.42. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.23 and a current ratio of 1.23.
Opus Genetics (NASDAQ:IRD - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The business had revenue of $3.08 million for the quarter, compared to analysts' expectations of $3.07 million. Opus Genetics had a negative return on equity of 697.94% and a negative net margin of 466.09%. On average, research analysts forecast that Opus Genetics, Inc. will post -1.22 earnings per share for the current fiscal year.
Analysts Set New Price Targets
IRD has been the topic of several recent analyst reports. Wall Street Zen downgraded Opus Genetics from a "hold" rating to a "sell" rating in a report on Saturday, November 15th. Piper Sandler started coverage on shares of Opus Genetics in a research report on Tuesday, November 25th. They issued an "overweight" rating and a $7.00 target price on the stock. Brookline Capital Management upgraded shares of Opus Genetics to a "strong-buy" rating in a research report on Monday, December 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Opus Genetics in a research note on Wednesday, October 8th. Finally, B. Riley initiated coverage on shares of Opus Genetics in a research note on Wednesday. They set a "buy" rating and a $9.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Opus Genetics presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.86.
View Our Latest Research Report on Opus Genetics
Institutional Investors Weigh In On Opus Genetics
Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in shares of Opus Genetics in the first quarter worth $26,000. Comerica Bank purchased a new position in Opus Genetics in the first quarter valued at about $29,000. Raymond James Financial Inc. increased its position in Opus Genetics by 95.6% in the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company's stock worth $37,000 after purchasing an additional 11,000 shares during the last quarter. Voss Capital LP bought a new position in Opus Genetics during the first quarter valued at approximately $147,000. Finally, Two Sigma Investments LP lifted its stake in Opus Genetics by 169.6% in the third quarter. Two Sigma Investments LP now owns 108,338 shares of the company's stock valued at $179,000 after acquiring an additional 68,148 shares during the last quarter. Institutional investors and hedge funds own 14.97% of the company's stock.
Opus Genetics Company Profile
(
Get Free Report)
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
